McCune-Albright syndrome: A Patient Guide
At a Glance
McCune-Albright syndrome is a rare condition caused by a random change in the GNAS gene in some body cells, not inherited from parents. It may affect bones, skin, and hormones, so care is tailored to each person's symptoms and requires regular monitoring.
McCune-Albright syndrome (MAS) is a rare and complex condition that arises from a random genetic change occurring very early in development. It is described as a mosaic disorder because the genetic change is only present in a subset of the body’s cells, while others remain unaffected [1][2]. This means that the condition is not inherited from parents, nor can it be passed down to children. In the affected cells, a gene called GNAS carries a mutation that keeps a cellular signaling switch permanently in the “on” position. This constant signal tells the cells to keep working even when they should be resting, which can lead to overactivity in the bones, skin, and hormone-producing glands [1][3].
Because the mutation is distributed in a mosaic pattern, no two people with MAS have the exact same symptoms or the same level of severity. The condition is classically defined by a “triad” of features: fibrous tissue replacing healthy bone (fibrous dysplasia), flat light-brown skin patches (café-au-lait macules), and overactive glands that produce excess hormones, such as those leading to early puberty [4][3]. However, a person does not need to have all three features to be diagnosed; in most cases, having two of these “cardinal” signs often supports a clinical diagnosis of the syndrome and prompts specialized care [5][6]. A single feature on its own, like an isolated skin spot, does not prove the syndrome but can prompt assessment for others.
What to Know Now
- Diagnosis: A clinical diagnosis is usually supported by characteristic symptoms and imaging. Genetic testing of tissue is sometimes used, but is generally reserved for when there is diagnostic uncertainty.
- Active Symptoms: Medical care focuses on the specific symptoms you or your child currently have.
- Routine Monitoring: You will need a baseline assessment, followed by an individualized schedule of monitoring to watch for changes.
- Urgent Symptoms: Any sudden loss of vision, severe uncontrolled bone pain, inability to bear weight, or rapidly progressive headaches should be evaluated immediately.
The management of MAS is highly individualized, focusing on the specific symptoms that are active for each person. Because the condition can involve the skeleton, skin, and several different endocrine glands, the best care is usually provided by a multidisciplinary team of experts. This team typically includes specialists in endocrinology, orthopedic surgery, and radiology, among others, working together to monitor bone health, hormone levels, and overall growth [7][8]. Regular active surveillance is key to staying ahead of the condition, as different symptoms may emerge at different ages [9].
While receiving a diagnosis of a rare disease can feel overwhelming, many people can manage symptoms effectively with individualized care, although monitoring and treatment needs vary substantially from person to person. Modern medicine offers various treatments to address bone pain, stabilize weakened bones, and balance hormone production. By building a relationship with a specialized care team and maintaining consistent monitoring, families and patients can navigate the complexities of MAS with confidence [7][3].
In this guide
6 chapters
Validation & Orientation: Understanding McCune-Albright Syndrome
Learn what McCune-Albright syndrome means, how mosaicism shapes symptoms, how doctors diagnose it, and what to expect from ongoing monitoring and care.
The Science of GNAS Mosaicism and Diagnosis
Learn how GNAS mosaicism causes McCune-Albright syndrome, how 2019 criteria support diagnosis, and why blood tests can be negative despite typical symptoms.
The Classic Triad: Skin, Bones, and Hormones
Learn how McCune-Albright syndrome affects skin, bones, and hormones, including café-au-lait spots, fibrous dysplasia, bone risks, and early puberty signs.
Endocrine Management: Balancing the Body's Hormones
Learn how McCune-Albright syndrome affects hormones, including early puberty, growth hormone excess, hyperthyroidism, phosphate wasting, testing, and treatment.
Skeletal Care & Orthopedics: Managing Fibrous Dysplasia
Learn how McCune-Albright syndrome affects bones, including pain medicines, orthopedic surgery, fracture warning signs, and when symptoms need urgent care.
Building Your Care Team and Long-Term Monitoring
Learn how McCune-Albright syndrome care teams coordinate long-term monitoring, bone and hormone checks, craniofacial screening, and mental health support.
Common questions in this guide
What causes McCune-Albright syndrome, and is it inherited?
What are the main features of McCune-Albright syndrome?
How is McCune-Albright syndrome diagnosed?
Which specialists may be involved in McCune-Albright syndrome care?
What monitoring does a person with McCune-Albright syndrome need?
Which symptoms of McCune-Albright syndrome need urgent medical attention?
Questions For You
Answer a question to get research tailored to you. Your answers are private.
Get notified when new evidence is published on McCune-Albright syndrome.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Based on the current clinical findings, do I (or does my child) meet the criteria for a clinical diagnosis of MAS?
- 2.Which specific organs or systems should we prioritize for screening based on the symptoms we are seeing today?
- 3.Can you help us coordinate our care with a specialized multidisciplinary center that has experience with MAS?
- 4.How does the mosaic nature of this condition affect the likelihood of new symptoms appearing as my child grows?
- 5.What is the communication plan between our different specialists, such as the endocrinologist and the orthopedic surgeon?
References
References (9)
- 1
Fibrous Dysplasia/McCune-Albright Syndrome: A Rare, Mosaic Disease of Gα s Activation.
Boyce AM, Collins MT
Endocrine reviews 2020; (41(2)) doi:10.1210/endrev/bnz011.
PMID: 31673695 - 2
Auxological and Endocrinological Features in Children With McCune Albright Syndrome: A Review.
Tufano M, Ciofi D, Amendolea A, Stagi S
Frontiers in endocrinology 2020; (11()):522 doi:10.3389/fendo.2020.00522.
PMID: 32849305 - 3
The Clinical Spectrum of McCune-Albright Syndrome and Its Management.
Spencer T, Pan KS, Collins MT, Boyce AM
Hormone research in paediatrics 2019; (92(6)):347-356 doi:10.1159/000504802.
PMID: 31865341 - 4
Clinical spectrum and uncommon features of McCune-Albright syndrome in children: a cohort study from a National Referral Center.
Bergignat S, Chapurlat R, Nicolino M, Perge K
Frontiers in endocrinology 2025; (16()):1531765 doi:10.3389/fendo.2025.1531765.
PMID: 40078582 - 5
Best practice management guidelines for fibrous dysplasia/McCune-Albright syndrome: a consensus statement from the FD/MAS international consortium.
Javaid MK, Boyce A, Appelman-Dijkstra N, et al.
Orphanet journal of rare diseases 2019; (14(1)):139 doi:10.1186/s13023-019-1102-9.
PMID: 31196103 - 6
McCune-Albright Syndrome: A Case Report and Review of Literature.
Nicolaides NC, Kontou M, Vasilakis IA, et al.
International journal of molecular sciences 2023; (24(10)) doi:10.3390/ijms24108464.
PMID: 37239810 - 7
A multidisciplinary care pathway improves quality of life and reduces pain in patients with fibrous dysplasia/McCune-Albright syndrome: a multicenter prospective observational study.
Meier ME, Hagelstein-Rotman M, van de Ven AC, et al.
Orphanet journal of rare diseases 2022; (17(1)):439 doi:10.1186/s13023-022-02588-z.
PMID: 36528764 - 8
Developing a Standardised Dataset for Natural History Studies in Fibrous Dysplasia/McCune-Albright Syndrome.
Priego Zurita AL, Bulaicon OO, Bryce J, et al.
Calcified tissue international 2025; (116(1)):68 doi:10.1007/s00223-025-01379-5.
PMID: 40316789 - 9
Extent of Extraskeletal Manifestations of Fibrous Dysplasia/McCune-Albright Syndrome in Patients with Mazabraud's Syndrome.
Hagelstein-Rotman M, Appelman-Dijkstra NM, Boyce AM, et al.
Calcified tissue international 2022; (110(3)):334-340 doi:10.1007/s00223-021-00918-0.
PMID: 34854944
This McCune-Albright syndrome guide is for educational purposes and does not replace medical advice. An endocrinologist and other members of your care team should interpret symptoms, test results, and monitoring needs for you or your child.